230 related articles for article (PubMed ID: 32224815)
1. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.
Davis S; Gralla J; Klem P; Stites E; Wiseman A; Cooper JE
Transplantation; 2020 Apr; 104(4):881-887. PubMed ID: 32224815
[TBL] [Abstract][Full Text] [Related]
2. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
[TBL] [Abstract][Full Text] [Related]
3. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
Whalen HR; Glen JA; Harkins V; Stevens KK; Jardine AG; Geddes CC; Clancy MJ
Transplantation; 2017 Feb; 101(2):430-436. PubMed ID: 26950724
[TBL] [Abstract][Full Text] [Related]
4. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
Davis S; Gralla J; Klem P; Tong S; Wedermyer G; Freed B; Wiseman A; Cooper JE
Am J Transplant; 2018 Apr; 18(4):907-915. PubMed ID: 28925597
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus Intrapatient Variability on Graft Outcomes in Adherent Renal Transplantation Patients: A Cross-Sectional Study.
Nafar M; Keshtkari S; Ziaie S; Firouzan A; Borumandnia N; Dalili N; Poorrezagholi F; Samadian F; Samavat S
Iran J Kidney Dis; 2024 May; 18(3):187-194. PubMed ID: 38904339
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
Solomon S; Colovai A; Del Rio M; Hayde N
Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
[TBL] [Abstract][Full Text] [Related]
7. Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk.
Baghai Arassi M; Gauche L; Schmidt J; Höcker B; Rieger S; Süsal C; Tönshoff B; Fichtner A
Pediatr Nephrol; 2022 Oct; 37(10):2503-2514. PubMed ID: 35166920
[TBL] [Abstract][Full Text] [Related]
8. Higher Serum Trough Levels of Tacrolimus Increase 5-Year Allograft Survival in Antibody Positive Renal Transplant Patients.
Peng ZG; Tian J
Clin Transpl; 2014; ():209-14. PubMed ID: 26281147
[TBL] [Abstract][Full Text] [Related]
9. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
10. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
11. High tacrolimus intra-patient variability is associated with graft rejection, and
Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Hebral AL; Bellière J; Kamar N
World J Gastroenterol; 2018 Apr; 24(16):1795-1802. PubMed ID: 29713132
[TBL] [Abstract][Full Text] [Related]
12. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development.
Rodrigo E; Segundo DS; Fernández-Fresnedo G; López-Hoyos M; Benito A; Ruiz JC; de Cos MA; Arias M
Transplantation; 2016 Nov; 100(11):2479-2485. PubMed ID: 26703349
[TBL] [Abstract][Full Text] [Related]
13. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation.
Park Y; Lee H; Eum SH; Kim HD; Ko EJ; Yang CW; Chung BH
Front Immunol; 2021; 12():746013. PubMed ID: 34659243
[TBL] [Abstract][Full Text] [Related]
14. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
Gathogo E; Harber M; Bhagani S; Levy J; Jones R; Hilton R; Davies G; Post FA;
Transplantation; 2016 Apr; 100(4):871-8. PubMed ID: 26413990
[TBL] [Abstract][Full Text] [Related]
15. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper.
Crespo M; Zárraga S; Alonso Á; Beneyto I; Díaz Corte C; Fernandez Rodriguez AM; Franco A; Hernández D; González-Roncero FM; Jiménez Martín C; Jimeno L; Lauzurica Valdemoros LR; Llorente S; Mazuecos A; Osuna A; Ramos JP; Rodríguez Benot A; Ruiz San Millán JC; Sánchez Fructuoso A; Torregrosa JV; Guirado L;
Transplantation; 2020 Aug; 104(8 Suppl 2):S1-S12. PubMed ID: 32658025
[No Abstract] [Full Text] [Related]
17. Patterns in Tacrolimus Variability and Association with
Piburn KH; Sigurjonsdottir VK; Indridason OS; Maestretti L; Patton MV; McGrath A; Palsson R; Gallo A; Chaudhuri A; Grimm PC
Clin J Am Soc Nephrol; 2022 Aug; 17(8):1194-1203. PubMed ID: 35882506
[TBL] [Abstract][Full Text] [Related]
18. Posttransplant Calcineurin Inhibitors Levels and Intrapatient Variability Are Not Associated With Long-term Outcomes Following Liver Transplantation.
Di Maira T; Sapisochin G; Lilly L; Fonés V; Berenguer M
Transplantation; 2020 Jun; 104(6):1201-1209. PubMed ID: 31609904
[TBL] [Abstract][Full Text] [Related]
19. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
20. Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant.
Shuker N; Bouamar R; Hesselink DA; van Gelder T; Caliskan K; Manintveld OC; Balk AH; Constantinescu AA
Exp Clin Transplant; 2018 Jun; 16(3):326-332. PubMed ID: 28969528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
